UK's biggest drugmakers see surprise profit bump, even as pharma grapples with U.S. policies

AstraZeneca and GSK both beat first-quarter profit expectations, with AstraZeneca core EPS at $2.58 vs. $2.53 expected and GSK core EPS at £0.47 vs. £0.43 expected. AstraZeneca also topped revenue forecasts at $15.3 billion, up 8% year-on-year, while GSK revenue was in line at £7.63 billion, up 5%. AstraZeneca reiterated its $80 billion revenue target for 2030 and highlighted positive late-stage trial progress, supporting a constructive outlook for the sector.

Analysis

The earnings beats matter less than the signal that both franchises are still compounding while European policy risk is becoming a larger capital-allocation variable. The market is effectively paying for two things here: visible near-term execution and a longer-duration option on pipeline monetization before any U.S. pricing regime can materially distort global launch economics. That makes the next 12-18 months the key window where operational momentum can outrun policy overhang.

The bigger second-order effect is not on these two names alone, but on the willingness of global pharma to prioritize launch sequencing, trial locations, and manufacturing allocation away from Europe. If U.S. net pricing is pressured through MFN-style reference effects, Europe risks becoming the residual market for launch timing and breadth, which would eventually feed back into lower incremental revenue per asset across the sector. That is a quiet but meaningful headwind for the entire ex-U.S. innovation ecosystem, with valuation multiple compression likely to show up first in companies whose growth cases depend on frequent pipeline repricing.

For AstraZeneca specifically, the setup is more asymmetric because the stock already trades like a pipeline winner and not just a defensive healthcare compounder. Positive late-stage readouts create a near-term catalyst stack, but they also raise the bar for any disappointment; with pharma, the move usually happens on the second derivative of data cadence rather than current-quarter beats. GSK is more of a cleaner quality-and-turnaround story, but with less obvious pipeline torque, so relative outperformance may be more dependent on execution consistency than on upside surprise.

NVS looks more vulnerable on a relative basis because it sits closer to the center of the policy debate while not having the same visible near-term catalyst density. If investors start to believe MFN effects will bite inside 18 months, the first rotation is likely from broad Europe pharma exposure into the most self-help-heavy winners, which should widen dispersion within large-cap pharma rather than produce a uniform sector re-rating. The contrarian risk is that the market may be underestimating how long U.S. policy implementation takes; if actual pricing transmission remains delayed, these stocks could continue grinding higher on earnings and pipeline headlines alone.

Key Decisions for Investors

• Long AZN vs short NVS for a 3-6 month relative-value trade: AZN has more visible near-term catalyst density and better insulation from a Europe-policy repricing; target 8-12% relative outperformance with a stop if NVS stabilizes on policy clarification.
• Accumulate GSK on pullbacks over the next 1-2 weeks as a quality compounder with less headline risk than peers; upside is steadier but lower beta, making it attractive for defensive healthcare exposure if broader risk assets wobble.
• Buy AZN call spreads 6-9 months out to express pipeline upside while capping premium bleed; the risk/reward is strongest into the next data window, where a single additional positive readout could re-rate the stock without requiring sector-wide multiple expansion.
• Hedge a long Europe-pharma basket with a short NVS overlay for 1-2 quarters if policy headlines intensify; NVS is the cleanest way to express the market's first-order fear that U.S. pricing pressure will slow ex-U.S. launch economics.
• Avoid chasing the broad sector after the earnings gap higher; wait for a 3-5% retracement to establish longs, since the near-term upside is more likely to come from pipeline catalysts than from further multiple expansion.